These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 21151388)
1. Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma. Liu J; Brown RE Int J Clin Exp Pathol; 2010 Oct; 3(8):755-62. PubMed ID: 21151388 [TBL] [Abstract][Full Text] [Related]
2. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma. Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746 [TBL] [Abstract][Full Text] [Related]
3. The role of epithelial mesenchymal transition markers in thyroid carcinoma progression. Montemayor-Garcia C; Hardin H; Guo Z; Larrain C; Buehler D; Asioli S; Chen H; Lloyd RV Endocr Pathol; 2013 Dec; 24(4):206-12. PubMed ID: 24126800 [TBL] [Abstract][Full Text] [Related]
4. Cancer stem-like cell behavior in anaplastic thyroid cancer: A challenging dilemma. Haghpanah V; Fallah P; Naderi M; Tavakoli R; Soleimani M; Larijani B Life Sci; 2016 Feb; 146():34-9. PubMed ID: 26772823 [TBL] [Abstract][Full Text] [Related]
5. Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers. Hardin H; Montemayor-Garcia C; Lloyd RV Hum Pathol; 2013 Sep; 44(9):1707-13. PubMed ID: 23528862 [TBL] [Abstract][Full Text] [Related]
6. Expression of epithelial-mesenchymal transition regulators TWIST, SLUG and SNAIL in follicular thyroid tumours may relate to widely invasive, poorly differentiated and distant metastasis. Wu J; Zhang Y; Cheng R; Gong W; Ding T; Zhai Q; Wang Y; Meng B; Sun B Histopathology; 2019 Apr; 74(5):780-791. PubMed ID: 30368884 [TBL] [Abstract][Full Text] [Related]
7. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156 [TBL] [Abstract][Full Text] [Related]
8. Detection and prognostic relevance of cytokeratin 20 in differentiated and anaplastic thyroid carcinomas by RT-PCR. Schmitz-Winnenthal FH; Weckauf H; Haufe S; Hinz U; Z'graggen K; Klar E; Büchler MW; Weber T Surgery; 2003 Dec; 134(6):964-71; discussion 971-2. PubMed ID: 14668729 [TBL] [Abstract][Full Text] [Related]
9. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500 [TBL] [Abstract][Full Text] [Related]
10. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance. Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857 [TBL] [Abstract][Full Text] [Related]
11. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572 [TBL] [Abstract][Full Text] [Related]
12. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer. Zhang Y; Wei J; Wang H; Xue X; An Y; Tang D; Yuan Z; Wang F; Wu J; Zhang J; Miao Y Oncol Rep; 2012 May; 27(5):1599-605. PubMed ID: 22322379 [TBL] [Abstract][Full Text] [Related]
13. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin(+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers. Mitra A; Satelli A; Xia X; Cutrera J; Mishra L; Li S Int J Cancer; 2015 Jul; 137(2):491-6. PubMed ID: 25487874 [TBL] [Abstract][Full Text] [Related]
14. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome. Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin. Liu J; Brown RE Int J Clin Exp Pathol; 2011; 4(8):755-64. PubMed ID: 22135723 [TBL] [Abstract][Full Text] [Related]
16. What is the clinical value of cancer stem cell markers in gliomas? Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423 [TBL] [Abstract][Full Text] [Related]
17. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas. Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809 [TBL] [Abstract][Full Text] [Related]
18. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients. Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633 [TBL] [Abstract][Full Text] [Related]
19. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma. Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106 [TBL] [Abstract][Full Text] [Related]